These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands. Yoshida R; Kaneyasu T; Ueki A; Yamauchi H; Ohsumi S; Ohno S; Aoki D; Baba S; Kawano J; Matsumoto N; Nagasaki M; Ueno T; Inari H; Kobayashi Y; Takei J; Gotoh O; Nishi M; Okamura M; Kaneko K; Okawa M; Suzuki M; Amino S; Inuzuka M; Noda T; Mori S; Nakamura S Breast Cancer; 2024 Nov; 31(6):1028-1036. PubMed ID: 39003386 [TBL] [Abstract][Full Text] [Related]
4. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study. Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080 [TBL] [Abstract][Full Text] [Related]
5. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers. Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374 [TBL] [Abstract][Full Text] [Related]
6. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661 [TBL] [Abstract][Full Text] [Related]
8. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas. Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208 [TBL] [Abstract][Full Text] [Related]
9. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer. Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755 [TBL] [Abstract][Full Text] [Related]
11. [Application of next-generation sequencing in detection of BRCA1/2 and homologous recombination repair pathway multi-genes germline mutation and correlation analysis]. Chen YL; Zhuo ZL; Liu C; Xie F; Yang ZY; Liu PF; Wang S; Zhao XT Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):302-311. PubMed ID: 35381651 [No Abstract] [Full Text] [Related]
12. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India. Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120 [TBL] [Abstract][Full Text] [Related]
13. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291 [TBL] [Abstract][Full Text] [Related]
14. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial. Shore N; Gazi M; Pieczonka C; Heron S; Modh R; Cahn D; Belkoff LH; Berger A; Mazzarella B; Veys J; Idom C; Morris D; Jayram G; Engelman A; Bukkapatnam R; Dato P; Bevan-Thomas R; Cornell R; Wise DR; Hardwick MK; Hernandez RD; Rojahn S; Layman P; Hatchell KE; Heald B; Nussbaum RL; Nielsen SM; Esplin ED Eur Urol Oncol; 2023 Oct; 6(5):477-483. PubMed ID: 37574391 [TBL] [Abstract][Full Text] [Related]
16. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646 [TBL] [Abstract][Full Text] [Related]
17. Rate of Pathogenic Germline Variants in Patients With Lung Cancer. Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258 [TBL] [Abstract][Full Text] [Related]
18. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study. Arrieta O; Caballé-Pérez E; Hernández-Pedro N; Romero-Nuñez E; Lucio-Lozada J; Castillo-Ruiz C; Acevedo-Castillo K; María Álvarez-Gómez R; Molina-Garay C; Jiménez-Olivares M; Carrillo-Sánchez K; Cristina Mendoza-Caamal E; Cardona AF; Remon J; Alaez-Verson C Lung Cancer; 2024 Aug; 194():107864. PubMed ID: 38945003 [TBL] [Abstract][Full Text] [Related]
20. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study. Hutchcraft ML; Zhang S; Lin N; Pickarski JC; Belcher EA; Wei S; Bocklage T; Miller RW; Villano JL; Cavnar MJ; Kim J; Arnold SM; Ueland FR; Kolesar JM JCO Precis Oncol; 2024 Jan; 8():e2300266. PubMed ID: 38295319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]